title: Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice.
abstract: OBJECTIVE
  This study evaluated the eradication rate of levofloxacin-containing rescue therapy by treatment duration in patients in whom previous first- and second-line treatment failed.
  
  
  METHODS
  Fifty-five patients with persistentHelicobacter pyloriinfection after first-line therapy and second-line therapy were studied in a single referral academic center. We compared the eradication rates by the treatment duration of third-line therapy.
  
  
  RESULTS
  Of 55 patients, 12 (21.8%) received rescue therapy for seven days, 24 (43.6%) received rescue therapy for 10 days, and 19 (34.5%) received rescue therapy for 14 days. The eradication rates of therapy with levofloxacin were 65.5% in the 55 enrolled patients and 73.5% in the 49 patients who underwent follow-up testing. In cases where follow-up testing was performed, the eradication rate of 7-day therapy was 58.3%, of 10-day 68.2%, and of 14-day therapy 93.3%. Eradication rate of 14-day therapy was higher than 7-day (p=0.06) and 10-day (p=0.108), but chance could not be ruled out in the difference among groups.
  
  
  CONCLUSIONS
  This study showed somewhat increasing ofH. pylorieradication rate by extending the duration of levofloxacin-containing rescue therapy to 14 days.
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Hyung Min
authors.initials: HM
authors.lastname: Noh
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Su Jin
authors.initials: SJ
authors.lastname: Hong
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Jae Pil
authors.initials: JP
authors.lastname: Han
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Kyung Woo
authors.initials: KW
authors.lastname: Park
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Yun Nah
authors.initials: YN
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Tae Hee
authors.initials: TH
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Bong Min
authors.initials: BM
authors.lastname: Ko
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Joon Seong
authors.initials: JS
authors.lastname: Lee
authors.affiliation: Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea.|Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea.
authors.forename: Moon Sung
authors.initials: MS
authors.lastname: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000658:Amoxicillin / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D017291:Clarithromycin / Q000627:therapeutic use; D005260:Female; D016481:Helicobacter Infections / Q000188:drug therapy* / Q000382:microbiology; D016480:Helicobacter pylori / Q000187:drug effects / Q000302:isolation & purification; D006801:Humans; D064704:Levofloxacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D054328:Proton Pump Inhibitors / Q000627:therapeutic use; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D000900:Anti-Bacterial Agents; D054328:Proton Pump Inhibitors; D064704:Levofloxacin; D000658:Amoxicillin; D017291:Clarithromycin
keywords: Eradication; Helicobacter pylori; Levofloxacin; Rescue therapy